Effector Free Cash Flow Per Share vs Ptb Ratio Analysis

EFTR Stock

USD 0.0002 0.0004 66.67%

Effector Therapeutics financial indicator trend analysis is much more than just examining Effector Therapeutics latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Effector Therapeutics is a good investment. Please check the relationship between Effector Therapeutics Free Cash Flow Per Share and its Ptb Ratio accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Effector Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.

To learn how to invest in Effector Stock, please use our How to Invest in Effector Therapeutics guide.

Free Cash Flow Per Share vs Ptb Ratio

Free Cash Flow Per Share vs Ptb Ratio Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Effector Therapeutics Free Cash Flow Per Share account and Ptb Ratio. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Effector Therapeutics' Free Cash Flow Per Share and Ptb Ratio is 0.4. Overlapping area represents the amount of variation of Free Cash Flow Per Share that can explain the historical movement of Ptb Ratio in the same time period over historical financial statements of Effector Therapeutics, assuming nothing else is changed. The correlation between historical values of Effector Therapeutics' Free Cash Flow Per Share and Ptb Ratio is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Free Cash Flow Per Share of Effector Therapeutics are associated (or correlated) with its Ptb Ratio. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Ptb Ratio has no effect on the direction of Free Cash Flow Per Share i.e., Effector Therapeutics' Free Cash Flow Per Share and Ptb Ratio go up and down completely randomly.

Correlation Coefficient

0.4

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Free Cash Flow Per Share

The amount of cash a company generates after accounting for capital expenditures, divided by the number of outstanding shares. It represents the cash available for dividends, share buybacks, or debt repayment per share.

Ptb Ratio

Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.

Most indicators from Effector Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Effector Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Effector Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.

To learn how to invest in Effector Stock, please use our How to Invest in Effector Therapeutics guide.At this time, Effector Therapeutics' Issuance Of Capital Stock is relatively stable compared to the past year. As of 12/06/2025, Sales General And Administrative To Revenue is likely to grow to 3.47, though Enterprise Value Over EBITDA is likely to grow to (1.04).

	2022	2023	2024	2025 (projected)
Interest Expense	2.3M	2.9M	3.4M	2.1M
Depreciation And Amortization	53K	111K	99.9K	104.8K

Interest Expense Depreciation And Amortization

Effector Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Shares Outstanding	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Property Plant Equipment	Current Deferred Revenue	Long Term Debt	Common Stock Total Equity
Total Assets		0.71	-0.12	-0.32	0.95	0.88	-0.79	-0.84	0.3	0.41	0.94	0.33	0.92	0.82	1.0	0.77	0.99	0.6	0.23	1.0	-0.41	0.8	-0.88	-0.32	0.82	0.82
Short Long Term Debt Total	0.71		0.32	0.42	0.51	0.93	-0.68	-0.32	-0.29	0.83	0.56	0.45	0.85	0.38	0.71	0.93	0.66	0.88	-0.21	0.7	0.32	0.97	-0.61	-0.51	0.97	0.96
Other Current Liab	-0.12	0.32		0.48	-0.33	0.05	0.47	0.26	-0.26	0.14	-0.16	0.83	-0.14	-0.1	-0.13	-0.02	-0.12	0.08	-0.99	-0.13	0.46	0.23	0.5	-0.01	0.13	0.13
Total Current Liabilities	-0.32	0.42	0.48		-0.46	0.15	0.05	0.7	-0.75	0.58	-0.51	0.14	0.01	-0.43	-0.32	0.28	-0.4	0.39	-0.5	-0.32	0.99	0.3	0.25	-0.2	0.27	0.26
Total Stockholder Equity	0.95	0.51	-0.33	-0.46		0.73	-0.76	-0.87	0.5	0.17	0.89	0.17	0.83	0.9	0.95	0.65	0.94	0.37	0.42	0.95	-0.54	0.65	-0.87	-0.08	0.69	0.7
Net Tangible Assets	0.88	0.93	0.05	0.15	0.73		-0.84	-0.52	-0.16	0.77	0.73	0.33	0.98	0.56	0.88	0.95	0.83	0.88	0.05	0.87	0.05	0.95	-0.82	-0.52	0.97	0.97
Property Plant And Equipment Net	-0.79	-0.68	0.47	0.05	-0.76	-0.84		0.57	0.06	-0.64	-0.71	0.21	-0.91	-0.46	-0.8	-0.88	-0.75	-0.75	-0.56	-0.79	0.13	-0.74	0.97	0.44	-0.8	-0.8
Net Debt	-0.84	-0.32	0.26	0.7	-0.87	-0.52	0.57		-0.57	0.03	-0.95	-0.14	-0.6	-0.73	-0.84	-0.44	-0.88	-0.22	-0.37	-0.84	0.76	-0.44	0.71	0.02	-0.47	-0.48
Retained Earnings	0.3	-0.29	-0.26	-0.75	0.5	-0.16	0.06	-0.57		-0.69	0.37	0.12	-0.03	0.67	0.3	-0.24	0.35	-0.55	0.3	0.3	-0.74	-0.16	-0.14	0.45	-0.15	-0.14
Accounts Payable	0.41	0.83	0.14	0.58	0.17	0.77	-0.64	0.03	-0.69		0.26	0.11	0.69	-0.06	0.41	0.8	0.35	0.97	-0.09	0.41	0.51	0.73	-0.51	-0.78	0.75	0.73
Cash	0.94	0.56	-0.16	-0.51	0.89	0.73	-0.71	-0.95	0.37	0.26		0.24	0.79	0.71	0.94	0.64	0.97	0.49	0.28	0.94	-0.6	0.64	-0.82	-0.28	0.67	0.67
Non Current Assets Total	0.33	0.45	0.83	0.14	0.17	0.33	0.21	-0.14	0.12	0.11	0.24		0.2	0.43	0.32	0.15	0.33	0.14	-0.79	0.32	0.1	0.43	0.13	-0.05	0.35	0.36
Non Currrent Assets Other	0.92	0.85	-0.14	0.01	0.83	0.98	-0.91	-0.6	-0.03	0.69	0.79	0.2		0.63	0.92	0.94	0.88	0.82	0.24	0.92	-0.08	0.9	-0.92	-0.48	0.93	0.94
Other Assets	0.82	0.38	-0.1	-0.43	0.9	0.56	-0.46	-0.73	0.67	-0.06	0.71	0.43	0.63		0.81	0.42	0.8	0.1	0.17	0.81	-0.49	0.54	-0.61	0.15	0.54	0.56
Cash And Short Term Investments	1.0	0.71	-0.13	-0.32	0.95	0.88	-0.8	-0.84	0.3	0.41	0.94	0.32	0.92	0.81		0.77	0.99	0.6	0.25	1.0	-0.41	0.79	-0.88	-0.32	0.82	0.82
Common Stock Shares Outstanding	0.77	0.93	-0.02	0.28	0.65	0.95	-0.88	-0.44	-0.24	0.8	0.64	0.15	0.94	0.42	0.77		0.72	0.89	0.12	0.77	0.19	0.95	-0.81	-0.45	0.98	0.97
Other Current Assets	0.99	0.66	-0.12	-0.4	0.94	0.83	-0.75	-0.88	0.35	0.35	0.97	0.33	0.88	0.8	0.99	0.72		0.56	0.24	0.99	-0.49	0.74	-0.85	-0.32	0.76	0.77
Other Stockholder Equity	0.6	0.88	0.08	0.39	0.37	0.88	-0.75	-0.22	-0.55	0.97	0.49	0.14	0.82	0.1	0.6	0.89	0.56		0.0	0.6	0.3	0.82	-0.66	-0.76	0.84	0.83
Total Liab	0.23	-0.21	-0.99	-0.5	0.42	0.05	-0.56	-0.37	0.3	-0.09	0.28	-0.79	0.24	0.17	0.25	0.12	0.24	0.0		0.24	-0.5	-0.12	-0.59	-0.05	-0.03	-0.03
Total Current Assets	1.0	0.7	-0.13	-0.32	0.95	0.87	-0.79	-0.84	0.3	0.41	0.94	0.32	0.92	0.81	1.0	0.77	0.99	0.6	0.24		-0.41	0.79	-0.88	-0.32	0.82	0.82
Short Term Debt	-0.41	0.32	0.46	0.99	-0.54	0.05	0.13	0.76	-0.74	0.51	-0.6	0.1	-0.08	-0.49	-0.41	0.19	-0.49	0.3	-0.5	-0.41		0.21	0.33	-0.15	0.17	0.16
Common Stock	0.8	0.97	0.23	0.3	0.65	0.95	-0.74	-0.44	-0.16	0.73	0.64	0.43	0.9	0.54	0.79	0.95	0.74	0.82	-0.12	0.79	0.21		-0.7	-0.36	1.0	1.0
Property Plant Equipment	-0.88	-0.61	0.5	0.25	-0.87	-0.82	0.97	0.71	-0.14	-0.51	-0.82	0.13	-0.92	-0.61	-0.88	-0.81	-0.85	-0.66	-0.59	-0.88	0.33	-0.7		0.4	-0.76	-0.76
Current Deferred Revenue	-0.32	-0.51	-0.01	-0.2	-0.08	-0.52	0.44	0.02	0.45	-0.78	-0.28	-0.05	-0.48	0.15	-0.32	-0.45	-0.32	-0.76	-0.05	-0.32	-0.15	-0.36	0.4		-0.39	-0.37
Long Term Debt	0.82	0.97	0.13	0.27	0.69	0.97	-0.8	-0.47	-0.15	0.75	0.67	0.35	0.93	0.54	0.82	0.98	0.76	0.84	-0.03	0.82	0.17	1.0	-0.76	-0.39		1.0
Common Stock Total Equity	0.82	0.96	0.13	0.26	0.7	0.97	-0.8	-0.48	-0.14	0.73	0.67	0.36	0.94	0.56	0.82	0.97	0.77	0.83	-0.03	0.82	0.16	1.0	-0.76	-0.37	1.0

Click cells to compare fundamentals

Effector Therapeutics Account Relationship Matchups

Effector Therapeutics fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	16.7M	54.1M	29.1M	20.5M	23.6M	27.6M
Short Long Term Debt Total	13.0M	20.0M	20.3M	20.5M	23.6M	19.6M
Other Current Liab	82K	3.0M	2.9M	2.9M	3.4M	2.6M
Total Current Liabilities	8.8M	4.0M	25.1M	25.8M	29.7M	18.2M
Total Stockholder Equity	979K	17.3M	3.9M	(5.8M)	(6.7M)	(6.3M)
Property Plant And Equipment Net	126K	257K	352K	193K	173.7K	280.2K
Net Debt	(2.3M)	(29.7M)	11.6M	5.7M	6.5M	6.8M
Retained Earnings	(136.7M)	(120.9M)	(143.6M)	(179.4M)	(161.4M)	(169.5M)
Accounts Payable	347K	516K	1.5M	2.3M	2.7M	2.8M
Cash	15.2M	49.7M	8.7M	14.9M	17.1M	20.2M
Non Current Assets Total	126K	1.2M	1.1M	706K	811.9K	853.2K
Non Currrent Assets Other	(126K)	903K	711K	513K	590.0K	619.4K
Cash And Short Term Investments	15.2M	49.7M	26.3M	18.4M	21.1M	24.9M
Common Stock Shares Outstanding	598.6K	1.6M	1.6M	2.2M	2.5M	1.3M
Liabilities And Stockholders Equity	16.7M	54.1M	29.1M	20.5M	23.6M	27.6M
Other Current Assets	1.4M	3.2M	1.7M	1.4M	1.6M	1.9M
Other Stockholder Equity	4.5M	138.2M	147.5M	347.2M	399.2M	419.2M
Total Liab	148.9M	36.8M	25.2M	26.3M	23.7M	41.0M
Total Current Assets	16.6M	52.9M	28.0M	19.8M	22.8M	26.8M
Short Term Debt	6.0M	88K	20.2M	20.5M	23.6M	13.7M

Pair Trading with Effector Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Effector Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Effector Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Effector Stock

0.65	VINC	Vincerx Pharma, Common	Pair Corr
0.58	PANACEABIO	Panacea Biotec	Pair Corr
0.57	DRMA	Dermata Therapeutics Buyout Trend	Pair Corr
0.56	DXB	Dimerix	Pair Corr
0.55	EQ	Equillium	Pair Corr

The ability to find closely correlated positions to Effector Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Effector Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Effector Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Effector Therapeutics to buy it.

The correlation of Effector Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Effector Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Effector Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Effector Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Effector Stock Analysis

When running Effector Therapeutics' price analysis, check to measure Effector Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Effector Therapeutics is operating at the current time. Most of Effector Therapeutics' value examination focuses on studying past and present price action to predict the probability of Effector Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Effector Therapeutics' price. Additionally, you may evaluate how the addition of Effector Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2025 Macroaxis LLC